Skip to main content

Advertisement

SpringerLink
Log in

EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C

  • Original Article
  • Published:
Genes & Immunity Submit manuscript

Abstract

Interferon lambda 3 (IFNL3) and epidermal growth factor receptor (EGFR) single nucleotide polymorphisms (SNPs) may play a key role in the spontaneous clearance of hepatitis C virus (HCV) and treatment responses. The aim of this study was to evaluate the effect of IFNL3 SNPs and EGFR rs11506105 on treatment outcomes in patients with chronic HCV (CHC). IFNL3 SNPs and EGFR rs11506105 were genotyped by PCR-restriction fragment length polymorphism and PCR-sequencing, respectively, in 235 naïve patients with CHC infection. The frequency of rapid virologic response (RVR), complete early virologic response (cEVR) and sustained virologic response (SVR) were 52.3%, 76.2% and 64.7% respectively. The results of this study showed that RVR was associated with ALT (P=0.015), AST (P=0.020), IFNL3 rs12979860 (CC) (P=0.043), rs12980275 (AA) (P=1 × 10−4), and EGFR rs11506105 (AA) (P=0.010), and IFNL3 rs12979860 (CC) (P=0.048), rs12980275 (AA) (P=0.022), and EGFR rs11506105 (AA) (P=0.006) were correlated with cEVR. HCV genotype (P=0.007), IFNL3 rs12979860 (CC) (P=0.023), IFNL3 rs12980275 (AA) (P=1 × 10−4), EGFR rs11506105 (AA) (P=0.005), RVR (P=1 × 10−4), and cEVR (P=0.003) were significant predictors for SVR. These results, for the first time, revealed that beside IFNL3 SNPs, EGFR rs11506105 is strongly associated with RVR, cEVR and SVR. EGFR rs11506105 besides IFNL3 SNPs could predict treatment responses in CHC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Carapito R, Poustchi H, Kwemou M, Untrau M, Sharifi A, Merat S et al. Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected iranian population. Genes immun 2015; 16: 514–518.

    Article  CAS  Google Scholar 

  2. Lavanchy D . The global burden of hepatitis C. Liver Int 2009; 29: 74–81.

    Article  Google Scholar 

  3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318–327.

    Article  Google Scholar 

  4. Fateh A, Aghasadeghi MR, Keyvani H, Mollaie HR, Yari S, Hadizade Tasbiti A et al. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment. Asian Pac J Cancer Prev 2015; 16: 1873–1880.

    Article  Google Scholar 

  5. Fateh A, Aghasadeghi M, Siadat SD, Vaziri F, Sadeghi F, Fateh R et al. Comparison of three different methods for detection of IL28 rs12979860 polymorphisms as a predictor of treatment outcome in patients with hepatitis C virus. Osong Public Health Res Perspect 2016; 7: 83–89.

    Article  Google Scholar 

  6. Alavian SM, Hajarizadeh B, Lankarani KB, Sharafi H, Daryani NE, Merat S et al. Recommendations for the clinical management of hepatitis C in Iran: a consensus-based national guideline. Hepat Month 2016; 16 (8): e40959.

    Google Scholar 

  7. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’hUigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798–801.

    Article  CAS  Google Scholar 

  8. Dayyeh BKA, Gupta N, Sherman KE, de Bakker PI, Chung RT, Team ACTGAS. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 2011; 6: e25753.

    Article  Google Scholar 

  9. Rao H, Wei L, Lopez‐Talavera JC, Shang J, Chen H, Li J et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Gepatol 2014; 29: 545–553.

    Article  CAS  Google Scholar 

  10. Zheng H, Li M, Chi B, Wu X-x, Wang J, Liu D-W . IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2015; 39: 576–583.

    Article  CAS  Google Scholar 

  11. Komposch K, Sibilia M . EGFR Signaling in Liver Diseases. Int J Mol Sci 2015; 17: 30.

    Article  Google Scholar 

  12. Schneider MR, Wolf E . The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460–466.

    Article  CAS  Google Scholar 

  13. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589–595.

    Article  CAS  Google Scholar 

  14. Scheel TK, Rice CM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837–849.

    Article  CAS  Google Scholar 

  15. Badawy AAG, El‐Hindawi A, Hammam O, Moussa M, Gabal S, Said N . Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus‐induced hepatocarcinogenesis. Apmis 2015; 123: 823–831.

    Article  CAS  Google Scholar 

  16. Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM et al. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol 2016: 1–9.

  17. Divella R, Daniele A, Gadaleta C, Tufaro A, Venneri MT, Paradiso A et al. Circulating transforming growth factor-β and epidermal growth factor receptor as related to virus infection in liver carcinogenesis. Anticancer Res 2012; 32: 141–145.

    CAS  PubMed  Google Scholar 

  18. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.

    Article  CAS  Google Scholar 

  19. Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M . The genotype CC of IL‐28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV‐infected Pakistani patients. J Digest Dis 2015; 16: 293–298.

    Article  CAS  Google Scholar 

  20. Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD et al. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Digest Dis 2015; 16: 90–97.

    Article  CAS  Google Scholar 

  21. Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A et al. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World J Gastroenterol 2014; 20: 13146.

    Article  CAS  Google Scholar 

  22. Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011; 6: e17232.

    Article  CAS  Google Scholar 

  23. Aziz H, Raza A, Ali K, Khattak JZK, Irfan J, Gill ML . Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis 2015; 30: 91–97.

    Article  CAS  Google Scholar 

  24. Ling Q, Chen J, Zhou H, Zhong J, Chen Y, Ye Q et al. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms. Arch Virol 2015; 160: 1105–1112.

    Article  CAS  Google Scholar 

  25. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415–421.

    Article  CAS  Google Scholar 

  26. Shaikh N, Waryah AM, Devrajani BR, Rajput MI, Hayat AS, Shaikh S . IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. J Med Virol 2015; 87: 814–820.

    Article  CAS  Google Scholar 

  27. Akkız H, Akgöllü E, Bekar A, Yıldırım S, Sandıkçı M, Ülger Y et al. Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1. Clin Res Hepatol Gastroenterol 2015; 39: 711–717.

    Article  Google Scholar 

  28. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109–1116.

    Article  CAS  Google Scholar 

  29. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC . Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832–836.

    Article  CAS  Google Scholar 

  30. Liang TJ, Ghany MG . Therapy of hepatitis C—back to the future. N Engl J Med 2014; 370: 2043–2047.

    Article  Google Scholar 

  31. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD . New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Int Med 2012; 156: 279–290.

    Article  Google Scholar 

  32. Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T . Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenom J 2016; 16: 18–29.

    Article  CAS  Google Scholar 

  33. Venegas Santos ME, Villanueva Arancibia RA, González Lagos KV, Brahm Barril JR . IL28B polymorphisms associated with therapy responsee in Chilean chronic hepatitis C patients. World J Gastroenterol 2011; 17: 3636–3639.

    Article  Google Scholar 

  34. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S . MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evolut 2013; 30: 2725–2729.

    Article  CAS  Google Scholar 

  35. Rodriguez S, Gaunt TR, Day IN . Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505–514.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank all of the patients who participated in the study.

Author information

Authors and Affiliations

  1. Department of microbiology, Qom branch, Islamic Azad University, Qom, Iran

    M Asnavandi & M Zargar

  2. Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

    F Vaziri, F R Jamnani, A Fateh & S D Siadat

  3. Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran

    F Vaziri, F R Jamnani, A Fateh & S D Siadat

  4. Research Centre for Emerging and Reemerging infectious diseases, Pasteur Institute of Iran, Tehran, Iran

    S Gharibzadeh

  5. Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, Iran

    S Gharibzadeh

Authors
  1. M Asnavandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Zargar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Vaziri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F R Jamnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Gharibzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Fateh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S D Siadat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Fateh.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Genes and Immunity website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asnavandi, M., Zargar, M., Vaziri, F. et al. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun 18, 144–151 (2017). https://doi.org/10.1038/gene.2017.12

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gene.2017.12

  • Springer Nature Limited

This article is cited by

Search

Navigation